证券代码：002900 证券简称：哈三联 公告编号：2022-033 哈尔滨三联药业股份有限公司 关于举行 2021 年年度报告网上业绩说明会暨参加黑龙江省上市 公司投资者集体接待日活动通知的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为加强与广大投资者沟通交流，促进上市公司规范运作、健康发展，哈尔滨 三联药业股份有限公司（以下简称"公司"）将于 2022 年 5 月 12 日（周四） 14:30-16:30 举行 2021 年年度报告网上业绩说明会暨参加黑龙江省上市公司投资 者集体接待日活动，本次活动由黑龙江省上市公司协会联合深圳市全景网络有限 公司共同举办，公司将通过"全景路演"网上平台召开进行，投资者可登录"全景 路演"（https://rs.p5w.net/html/132395.shtml）参与在线交流。公司相关人员将与 投资者就公司治理，经营状况、发展战略、投资者保护等问题进行沟通。 出席本次年度网上业绩说明会的人员：公司董事长兼总裁秦剑飞先生，独立 董事曾国林先生，董事、副总裁兼董事会秘书赵庆福先生，董事、副总裁梁延飞 先生，财务总监赵 ...

哈尔滨三联药业股份有限公司 2022 年第一季度报告全文 证券代码：002900 证券简称：哈三联 公告编号：2022-030 哈尔滨三联药业股份有限公司 2022 年第一季度报告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误 导性陈述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的 真实、准确、完整。 3.第一季度报告是否经过审计 □ 是 √ 否 一、主要财务数据 (一)主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 256,694,410.27 | 230,179,061.88 | 11.52% | | 归属于上市公司股东的净利润（元） | -1,170,560.94 | 563,29 ...

Financial Performance - The company's operating revenue for 2021 was ¥945,799,422.97, a decrease of 29.36% compared to ¥1,338,882,990.74 in 2020[20]. - The net profit attributable to shareholders in 2021 was ¥350,951,064.21, a significant increase of 1,096.77% from ¥29,324,801.54 in 2020[20]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥148,479,133.39, reflecting a decline of 601.82% compared to -¥21,156,331.68 in 2020[20]. - The company's total assets increased by 23.47% to ¥3,065,517,046.80 at the end of 2021, up from ¥2,482,760,796.58 at the end of 2020[20]. - The basic earnings per share for 2021 was ¥1.13, representing a growth of 1,155.56% from ¥0.09 in 2020[20]. - The weighted average return on net assets was 18.11% in 2021, an increase of 16.48 percentage points from 1.63% in 2020[20]. - The net cash flow from operating activities was -¥12,533,851.80 in 2021, worsening by 178.09% from -¥4,507,046.05 in 2020[20]. - The company reported a total of ¥499,430,197.60 in non-recurring gains in 2021, compared to ¥50,481,133.22 in 2020[26]. - The total operating revenue for 2021 was approximately ¥945.8 million, a decrease of 29.36% compared to ¥1.34 billion in 2020[48]. - The pharmaceutical sector accounted for 95.14% of total revenue, generating ¥899.8 million, down 21.47% from the previous year[48]. Dividends and Share Capital - The company reported a cash dividend of 3.20 RMB per 10 shares (including tax) based on a total share base of 309,784,867 shares after repurchase[4]. - The company has a total share capital of 316,600,050 shares, with 6,815,183 shares repurchased[4]. - The company implemented a cash dividend policy, distributing a total of 99,131,157.44 CNY (including tax), which accounted for 100% of the total profit distribution[167]. - The cash dividend per 10 shares was set at 3.2 CNY (including tax), based on a total share capital of 316,600,050 shares, after deducting repurchased shares[168]. Business Operations and Strategy - The company has not changed its main business since its listing, indicating stability in operations[18]. - The company operates several wholly-owned subsidiaries, enhancing its market presence and operational capabilities[11]. - The company is actively involved in the development of innovative products and manufacturing upgrades to meet the evolving market demands[29]. - The company has a diverse product line covering various therapeutic areas, including neurological, cardiovascular, and anti-tumor diseases, which supports its vertical integration strategy[35]. - The company is focusing on developing new business lines, including animal drugs and health products, to create new profit growth points[46]. - The company has established a nationwide marketing system to adapt to intensified competition due to ongoing pharmaceutical reforms and policies[115]. - The company aims to enhance operational efficiency by focusing on projects with quicker returns amid industry challenges[96]. Research and Development - The company invested CNY 99.92 million in R&D during the reporting period, focusing on overcoming technical challenges and advancing projects like the consistency evaluation of generic drugs[41]. - The company employs 290 R&D personnel, accounting for approximately 19.09% of its total workforce, emphasizing its commitment to innovation and technology[37]. - Three products, including Ammonium Bromide Injection and Ondansetron Injection, successfully passed the consistency evaluation, enhancing the company's market position[41]. - New products such as the sodium omeprazole injection and the sodium chloride injection have been submitted for market approval, expected to create new growth points[65]. Market and Industry Trends - The pharmaceutical industry in China is experiencing a strong demand due to factors such as an aging population and increased healthcare awareness, with a long-term growth trend expected[28]. - The government aims for an average annual growth rate of over 8% in revenue and profit for the pharmaceutical industry over the next five years, emphasizing innovation and international development[29]. - The national medical insurance catalog was updated in December 2021, indicating a more scientific and standardized approach to drug inclusion[28]. Risk Management - The company faces risks including industry policy risks, drug research and development risks, and fluctuations in raw material prices[4]. - The company is actively managing risks related to raw material price fluctuations and supply interruptions by monitoring market trends and securing procurement agreements[117]. Governance and Compliance - The company has established a robust internal audit system to effectively control risks and ensure compliance[131]. - The company has a comprehensive internal management and control system tailored to its development needs[138]. - The company has established independent financial accounting departments and maintains independent bank accounts, ensuring no interference from controlling shareholders in financial decisions[136]. - The company has conducted 6 shareholder meetings during the reporting period, ensuring compliance with governance regulations[124]. Environmental Responsibility - The company is classified as a key pollutant discharge unit, with specific emissions data reported for various pollutants[179]. - The total emissions of sulfur dioxide were reported at 11,377.4 kg, within the regulatory limit of 49,280 kg[179]. - The company has implemented measures to ensure compliance with environmental standards, with no instances of exceeding discharge limits reported[179]. - The company has invested over 10 million yuan in environmental protection since its establishment, with 1.39 million yuan spent in 2021 for pollution detection and maintenance of environmental facilities[196]. Employee Management - The total number of employees at the end of the reporting period was 1,519, with 1,156 in the parent company and 363 in major subsidiaries[161]. - The employee training program included systematic internal training and external training to enhance technical skills and management capabilities[164]. - The company maintained a competitive salary policy, with fixed salaries ensuring stable income and performance-based incentives to motivate employees[162]. - The total number of technical personnel was 658, highlighting a strong emphasis on technical expertise within the workforce[161].

Financial Performance - Revenue for Q3 2021 was CNY 233,828,492.90, a decrease of 31.08% compared to the same period last year[4] - Net profit attributable to shareholders was CNY -46,541,203.45, a decline of 682.09% year-on-year[4] - Basic earnings per share were CNY -0.15, down 650.00% from the previous year[4] - Total operating revenue for the third quarter was ¥707,663,354.04, a decrease from ¥966,463,406.42 in the previous period[18] - Net profit for the period reached ¥539,038,150.98, significantly higher than ¥20,064,066.28 in the same period last year[20] - Operating profit increased to ¥550,237,027.95 from ¥31,296,792.28 year-on-year[19] - Basic and diluted earnings per share were both ¥1.74, compared to ¥0.07 in the previous year[20] Assets and Liabilities - Total assets increased to CNY 3,039,905,997.83, representing a growth of 22.44% compared to the end of the previous year[5] - Total assets as of the end of the reporting period were ¥3,039,905,997.83, up from ¥2,482,760,796.58[16] - Total liabilities increased to ¥734,072,891.55 from ¥691,183,051.92[16] - The company reported a total asset value of 2,482,760,796.58 CNY as of September 30, 2021[26] - Total liabilities amounted to CNY 691,183,051.92, with current liabilities at CNY 588,839,686.79[27] - The total equity attributable to shareholders reached CNY 1,775,280,766.14, while total equity was CNY 1,791,577,744.66[28] Cash Flow - Cash flow from operating activities showed a net outflow of CNY -16,119,145.36, reflecting a 76.83% increase in cash outflow year-to-date[4] - The net cash flow from operating activities for Q3 2021 was -16,119,145.36 CNY, an improvement from -69,554,061.33 CNY in Q3 2020[22] - Total cash inflow from operating activities decreased to 814,839,472.33 CNY, down 31% from 1,183,661,019.44 CNY in the previous year[22] - Cash outflow from operating activities also decreased to 830,958,617.69 CNY, compared to 1,253,215,080.77 CNY in Q3 2020, marking a 34% reduction[22] - The net cash flow from investing activities was -254,382,213.83 CNY, a significant decline from 167,825,057.20 CNY in the same period last year[23] - Cash inflow from investing activities totaled 649,008,219.87 CNY, down 42% from 1,122,348,613.85 CNY in Q3 2020[23] - Cash outflow from investing activities was 903,390,433.70 CNY, slightly lower than 954,523,556.65 CNY in the previous year[23] - The net cash flow from financing activities was -89,986,493.91 CNY, compared to a positive flow of 10,122,397.52 CNY in Q3 2020[23] - Cash inflow from financing activities increased to 413,065,600.00 CNY, up from 324,700,063.16 CNY in the previous year[23] - The ending cash and cash equivalents balance was 299,483,683.36 CNY, down from 574,137,597.75 CNY at the end of Q3 2020[23] Investments - Investment income surged to CNY 588,101,455.17, a remarkable increase of 4987.48% compared to the same period last year[9] - The company reported investment income of ¥588,101,455.17, a significant increase from ¥11,559,771.62 year-on-year[19] - The company reported a significant increase in long-term equity investments, which rose by 3960.14% to CNY 605,541,373.38[9] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,441, with no preferred shareholders[12] - The top shareholder, Qin Jianfei, holds 39.07% of the shares, with 92,778,750 shares pledged[12] Operational Efficiency - Operating costs decreased to CNY 227,988,408.31, down 32.41% year-on-year due to the divestment of certain business operations[9] - The company experienced a 35.58% reduction in cash paid for operating activities, amounting to ¥415,499,475.35, due to decreased marketing and management expenses[10] - The company reported a 40.63% decrease in cash paid for purchasing goods and services, totaling ¥216,248,304.32, due to reduced payments for raw materials[10] - Cash paid for dividends and profit distribution decreased by 65.44% to ¥32,153,230.75, reflecting a reduction in shareholder dividends during the reporting period[10] Other Financial Information - The company received government subsidies amounting to CNY 1,958,793.99 during the reporting period, contributing to its financial performance[6] - The fair value change income for the reporting period was ¥7,655,403.86, a significant increase of 124.32% compared to the previous year, primarily due to gains from risk investments and expected financial management income[10] - The cash received from tax refunds increased by 82.34% to ¥24,215,995.98, attributed to higher tax refunds received during the reporting period[10] - The cash flow from the sale of fixed assets increased dramatically by 3,282.66%, reaching ¥11,591,965.32, due to an increase in asset disposals during the reporting period[10] Compliance and Standards - The company has implemented new leasing standards effective from January 1, 2021, impacting the financial statements[28] - The third-quarter report was not audited[29]

哈尔滨三联药业股份有限公司 2021 年半年度报告全文 2021 年半年度报告 哈尔滨三联药业股份有限公司 2021-069 2021 年 08 月 1 哈尔滨三联药业股份有限公司 2021 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人赵志成及会计机构负责人(会计主 管人员)翟明卉声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临行业政策风险、新药研发风险、原材料价格波动及供应中断 风险、募投项目不达预期的风险、风险投资收益波动的风险等，详细内容已在 本报告第三节"管理层讨论与分析（十）、公司面临的风险和应对措施"部分予 以描述。敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 第一节 | 重要提示、目录和释义 | | 2 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 ...

Financial Performance - The company's operating revenue for Q1 2021 was ¥230,179,061.88, a decrease of 20.30% compared to ¥288,795,847.25 in the same period last year[8] - Net profit attributable to shareholders was ¥563,299,946.56, representing a significant increase of 1,660.87% from ¥31,989,844.02 year-on-year[8] - The net profit after deducting non-recurring gains and losses was -¥13,367,118.30, a decrease of 1,957.41% compared to ¥719,665.24 in the previous year[8] - The basic earnings per share rose to ¥1.78, up 1,680.00% from ¥0.10 in the same period last year[8] - The company reported a significant increase in undistributed profits, rising to CNY 876,849,656.40 from CNY 341,231,297.92, an increase of approximately 157%[39] - The company expects a significant increase in net profit for the year, projecting a net profit of CNY 55,000 million, which is a 1,856.54% increase compared to the previous year[27] - Basic earnings per share are projected to be CNY 1.74, reflecting an increase of 1,859.68% compared to the previous year[27] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,029,396,416.51, an increase of 22.02% from ¥2,482,760,796.58 at the end of the previous year[8] - The total owner's equity increased to CNY 2,354,821,384.90 from CNY 1,791,577,744.66, marking an increase of about 31.4%[39] - Total liabilities decreased to CNY 674,575,031.61 from CNY 691,183,051.92, a reduction of approximately 2.4%[38] - The total assets reached CNY 3,129,172,534.87, compared to CNY 2,582,157,257.32 in the previous period, reflecting growth in the company's asset base[45] - Total liabilities decreased to CNY 561,592,080.70 from CNY 586,699,473.07 in the previous period[45] Cash Flow - The net cash flow from operating activities was -¥53,689,535.89, an improvement of 23.24% compared to -¥69,947,180.42 in the previous year[8] - The cash flow from operating activities showed a net outflow of CNY -53,689,535.89, an improvement from CNY -69,947,180.42 in the same period last year[54] - The cash inflow from investment activities was 20,183,375.58 CNY, compared to 367,625,156.95 CNY in the previous year, indicating a decrease in investment activity[58] - The net cash flow from investment activities was -336,969,016.27 CNY, indicating a significant outflow compared to the previous year's outflow of -8,908,778.33 CNY[58] - The cash flow from financing activities showed a net inflow of CNY 56,701,847.86, compared to CNY 9,814,639.46 in the previous year, reflecting a positive trend[55] Investments - The company reported non-recurring gains of ¥576,667,064.86, primarily due to the investment in 100% equity of Harbin Beixing Pharmaceutical Co., Ltd.[9] - Investment income surged by 8582.81% to ¥568,753,081.17, resulting from a 100% equity investment in Harbin Beixing Pharmaceutical Co., Ltd.[17] - The company made an investment in Harbin Fuyijia Technology Co., Ltd., acquiring 5% equity, resulting in an investment income of ¥56,649,000[19] - The company has committed a total investment of CNY 90,011.90 million for various projects, with a cumulative investment of CNY 28,980.84 million, representing 32.2% of the total commitment[24] Operational Changes - The marketing strategy is being adjusted to enhance the sales service system and improve market control capabilities[25] - The company adjusted its financial statements in accordance with the new leasing standards effective from January 1, 2021[63] - The company reported a long-term receivable of CNY 205,234,963.50, unchanged from the previous period[65] Shareholder Information - The total number of shareholders at the end of the reporting period was 37,766, with the top shareholder holding 39.07% of the shares[12]

Financial Performance - The company's operating revenue for 2020 was ¥1,338,882,990.74, a decrease of 36.31% compared to ¥2,102,061,189.57 in 2019[19]. - The net profit attributable to shareholders for 2020 was ¥29,324,801.54, down 83.45% from ¥177,184,368.25 in 2019[19]. - The net profit after deducting non-recurring gains and losses was -¥21,156,331.68 in 2020, a decline of 117.85% compared to ¥118,531,558.40 in 2019[19]. - The net cash flow from operating activities was -¥4,507,046.05 in 2020, a decrease of 101.41% from ¥320,140,786.74 in 2019[19]. - The basic and diluted earnings per share for 2020 were both ¥0.09, down 84.21% from ¥0.57 in 2019[19]. - The total assets at the end of 2020 were ¥2,482,760,796.58, a decrease of 7.09% from ¥2,672,123,690.27 at the end of 2019[19]. - The net assets attributable to shareholders at the end of 2020 were ¥1,775,280,766.14, down 3.13% from ¥1,832,695,727.36 at the end of 2019[19]. - The company reported a quarterly operating revenue of ¥372,419,584.32 in Q4 2020, with a net profit of ¥7,164,755.28[23]. - The company received government subsidies amounting to ¥82,859,947.05 in 2020, an increase compared to ¥38,683,531.09 in 2019[24]. - The total non-recurring gains and losses for 2020 amounted to ¥50,481,133.22, compared to ¥58,652,809.85 in 2019[24]. Shareholder Information - The company reported a total share capital of 316,600,050 shares as of December 31, 2020, with a cash dividend of 0.8 RMB per 10 shares to all shareholders[5]. - The company has a total of 309,784,867 shares available for dividend distribution after accounting for repurchased shares[5]. - The proposed cash dividend for 2020 is 0.8 yuan per share, totaling approximately 24.78 million yuan, pending shareholder approval[111]. - The cash dividend in 2020 represented 84.51% of the net profit attributable to ordinary shareholders[113]. - The total distributable profit for 2020 was reported at 341,231,297.92 CNY[114]. - The company has committed to maintaining a minimum cash dividend ratio of 20% during significant capital expenditure phases[114]. - The company’s cash dividend distribution strategy reflects a focus on returning value to shareholders while managing capital expenditures[114]. Risks and Challenges - The company faces risks including industry policy changes, new drug development risks, and fluctuations in raw material prices[5]. - The COVID-19 pandemic and the implementation of key monitored drug policies significantly impacted the company's main business operations[28]. - New drug development poses risks due to high costs and long cycles, necessitating careful project selection and management[102]. - The pharmaceutical industry is transitioning from rapid growth to high-quality development, facing challenges such as price reductions and increased market concentration[93]. Research and Development - R&D investment for the year was 112.0192 million yuan, accounting for 8.37% of the company's operating income[41]. - The company has a total of 295 R&D personnel, accounting for approximately 17.61% of the total workforce[35]. - The company is focusing on developing new products such as freeze-dried oral disintegrating tablets and new transdermal patches[65]. - The company activated 4 dormant products and successfully expanded its product lineup[42]. Corporate Governance and Compliance - The company emphasizes the importance of accurate financial reporting and has declared that its financial statements are true, accurate, and complete[4]. - The company has established a modern corporate governance structure, including a board of directors and various specialized committees[157]. - The company has implemented measures to stabilize stock prices, including withholding compensation for non-compliant executives for 10 trading days following a failure to act[117]. - The company has a long-term commitment to comply with all regulations and commitments made during the IPO process[116]. Social Responsibility and Environmental Initiatives - The company has invested over ¥10 million in environmental protection since its establishment, with an investment of over ¥350,000 in 2020[169]. - During the COVID-19 pandemic, the company donated nearly ¥1.5 million in cash and medicines to support the fight against the virus in Wuhan, including over 270,000 vials of medication[175]. - The company has implemented measures to comply with national air pollution control policies, including the removal of two coal-fired boilers and the installation of a gas boiler[184]. - The company has established a recyclable waste storage area for materials such as cardboard and plastic[185]. Market Position and Strategy - The company has a diverse product pipeline and a nationwide sales network, enhancing its competitive position in the pharmaceutical industry[30]. - The pharmaceutical industry is expected to continue growing due to factors such as aging population and consumption upgrades[29]. - The company aims to achieve low-cost operations through improved production efficiency and quality control, while implementing automation[99]. - The company will actively seek high-quality acquisition targets to enhance its core business and drive high-quality development[100].

证券代码：002900 证券简称：哈三联 公告编号：2020-071 哈尔滨三联药业股份有限公司 关于参加投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨三联药业股份有限公司（以下简 称"公司"）将参加由黑龙江省上市公司协会、深圳市全景网络有限公司共同举 办的"黑龙江省上市公司 2020 年度投资者网上集体接待日"活动，现将有关事 项公告如下： 本次集体接待日活动将通过深圳市全景网络有限公司提供的互联网平台举 行，投资者可以登录"全景•路演天下"网站（http://rs.p5w.net）参与公司本次 投资者集体接待日活动，时间为 2020 年 11 月 12 日（周四）14:00 至 16:30。 届时公司董事、副总经理兼董事会秘书赵庆福先生、副总经理兼财务总监韩 冰女士将通过网络在线问答互动的形式，与投资者就公司治理、发展经营情况和 可持续发展等投资者关注的问题进行交流。 欢迎广大投资者积极参与。 特此公告。 哈尔滨三联药业股份有限公司 董事会 2020 年 11 月 9 日 1 ...

Financial Performance - Operating revenue for the reporting period was CNY 339,293,038.86, down 32.77% year-on-year, and CNY 966,463,406.42 for the year-to-date, down 40.75%[7] - Net profit attributable to shareholders was a loss of CNY 5,950,895.85, a decrease of 117.61% year-on-year, and CNY 22,160,046.26 for the year-to-date, down 85.30%[7] - Basic earnings per share for the reporting period was -CNY 0.02, a decrease of 118.18% year-on-year, and CNY 0.07 for the year-to-date, down 85.42%[7] - Total revenue decreased by 40.75% to ¥966,463,406.42 compared to ¥1,631,127,186.84 in the same period last year, primarily due to the impact of COVID-19 on business operations and logistics[15] - The estimated cumulative net profit for the year is projected to be ¥26 million, a decrease of 85.05% compared to the previous year's ¥38 million[25] - Basic earnings per share are expected to be ¥0.08, down 85.96% from ¥0.12 in the same period last year[25] - The company reported a 76.93% decrease in income tax expenses to ¥11,150,518.35, correlating with the decline in total profit[16] - The company reported a net cash outflow from operating activities of ¥69,554,061.33, compared to a net inflow of ¥279,304,766.42 in the same period last year[61] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,468,487,161.09, a decrease of 7.62% compared to the end of the previous year[7] - Total liabilities decreased to ¥683.48 million from ¥820.44 million year-over-year[37] - The company's equity attributable to shareholders decreased to ¥1.77 billion from ¥1.83 billion at the end of 2019[38] - The company's total assets amounted to CNY 2,562,770,818.84, slightly down from CNY 2,594,310,195.91[41] - Total liabilities decreased to CNY 572,918,453.89 from CNY 636,666,439.76 year-on-year[41] - The company's total equity reached approximately $1.96 billion as of Q3 2020[75] - Short-term borrowings increased by 55.28% to ¥279,506,863.16 from ¥180,000,000.00, reflecting new bank loans during the reporting period[15] Cash Flow - The net cash flow from operating activities was CNY 25,123,503.26, down 84.89% compared to the same period last year[7] - The company generated ¥1,183,661,019.44 in cash inflows from operating activities, down 34.5% from ¥1,807,621,940.65 in the previous year[61] - The net cash flow from investing activities was ¥167,825,057.20, compared to a net outflow of ¥90,278,640.89 in the same period last year[62] - The company’s total operating cash inflow was 1,011,758,540.38 CNY, compared to 1,314,944,648.90 CNY in the previous period[63] - The net cash flow from investment activities was 199,719,056.76 CNY, a turnaround from -82,101,423.99 CNY in the previous period[65] Shareholder Information - The company reported a total of 20,999 common shareholders at the end of the reporting period[11] - The largest shareholder, Qin Jianfei, holds 39.07% of the shares, with a total of 123,705,000 shares, of which 36,110,000 are pledged[11] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] - The company repurchased 6,815,183 shares, accounting for 2.1526% of total share capital, with a total transaction amount of ¥85,754,696.02[17] Government Support and Subsidies - The company received government subsidies amounting to CNY 71,341,708.00, primarily related to government support and deferred income amortization[8] - Other income rose by 118.49% to ¥70,903,473.13, driven by an increase in government subsidies received[15] Investment Projects - The company reported a total investment of RMB 74,783 million in the pharmaceutical production base construction project, with a cumulative input of RMB 24,515.49 million, achieving 32.78% of the planned progress as of September 2022[23] - The marketing and service network center project has a total investment of RMB 5,093.9 million, with an input of RMB 2,960.59 million, reaching 58.12% of the planned progress as of June 2021[23] - The total amount of funds raised for investment projects is RMB 90,011.9 million, with a cumulative input of RMB 27,527.56 million[23] - The pharmaceutical production base construction project is experiencing delays due to the impact of the COVID-19 pandemic and changes in market conditions[23] Research and Development - Research and development expenses for Q3 2020 were CNY 25,256,016.29, compared to CNY 20,540,569.60 in the previous year[44] - Research and development expenses increased to ¥80,481,766.68, up from ¥62,905,822.61, representing a growth of 28%[52] - The company is currently optimizing production lines and introducing innovative technologies to enhance production automation and capacity, aiming to improve market competitiveness[23] - The engineering technology research center project is in the concept design phase, with a focus on attracting top R&D talent and enhancing product development capabilities[23] Market Conditions and Strategy - The company is adjusting its marketing strategies and optimizing its sales service system in response to significant changes in national pharmaceutical policies[23] - The company anticipates a significant decline in operating revenue due to adjustments in the national key monitoring reasonable drug use catalog[26] - Fixed expenses, including asset depreciation, are expected to remain stable despite the revenue decline, while R&D expenses are projected to increase compared to the previous year[26]

哈尔滨三联药业股份有限公司 2020 年半年度报告全文 哈尔滨三联药业股份有限公司 2020 年半年度报告 2020-049 2020 年 08 月 1 哈尔滨三联药业股份有限公司 2020 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人秦剑飞、主管会计工作负责人韩冰及会计机构负责人(会计主管 人员)赵志成声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 公司可能面临新冠肺炎疫情影响的风险、行业政策变化风险、新药研发风 险、原材料价格波动及供应风险、药品招标降价的风险、募投项目实施的风险、 风险投资收益波动的风险等，详细内容已在本报告第四节"经营情况讨论与分 析（十）、公司面临的风险和应对措施"部分予以描述。敬请广大投资者注意投 资风险。 | | | | 第一节 重要提示、目录和释义 | 2 | | --- | --- | | 第二节 公司简介和主要财务指标 | 6 | | 第三节 公司业务概要 | ...